Drugs / ACTR087
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03266692 | Feb 2018 → Oct 2019 | plasma cell myeloma | Cogent Biosciences, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02776813 | Aug 2016 → Feb 2020 | lymphoma | Cogent Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACTR087 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03266692 ↗ |
| Modality | Cell therapy | “autologous T-cell product expressing ACTR” NCT02776813 ↗ |